Icatibant

Active ingredient: Icatibant Acetate

In short: Icatibant injection is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.

Forms & strengthsIcatibant injection is supplied in a prefilled syringe delivering 30 mg icatibant. Each syringe delivers 3 mL solution with a concentration of 10 mg per mL.
LabelAlembic Pharmaceuticals Limited
Label updatedJul 03, 2025

What is Icatibant used for?

Icatibant injection is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.

Icatibant dosage

The recommended dose of Icatibant injection is 30 mg administered by subcutaneous (SC) injection in the abdominal area. Additional doses may be administered at intervals of at least 6 hours if response is inadequate or if symptoms recur. No more than 3 doses may be administered in any 24 hour period.

Icatibant injection should be inspected visually for particulate matter and discoloration prior to administration. The drug solution should be clear and colorless. Do not administer if the product contains particulates or is discolored.

Attach the provided 25 gauge needle to the syringe hub and screw on securely. Do not use a different needle. Disinfect the injection site and administer Icatibant injection by subcutaneous injection over at least 30 seconds. Discard unused portion.

Patients may self-administer Icatibant injection upon recognition of symptoms of an HAE attack after training under the guidance of a healthcare professional .

How to take Icatibant — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).

Patients may self-administer Icatibant injection upon recognition of an HAE attack after training under the guidance of a healthcare professional.

Patients with laryngeal symptoms should seek medical attention immediately in an appropriate healthcare facility after administration of Icatibant injection .

Injection site reactions are reported in most patients after administration of Icatibant injection. Other adverse reactions reported after administration of Icatibant injection include pyrexia, increase in transaminases, dizziness, and rash .

Tiredness, drowsiness, and dizziness have been reported following the use of Icatibant injection. Patients should be advised not to drive or use machinery if they feel tired or dizzy.

Manufactured by:

Alembic Pharmaceuticals Limited Karakhadi 391450, Gujarat, India.

Revised: January 2025

Warnings & precautions

Do not take this medicine if: None.

Given the potential for airway obstruction during acute laryngeal HAE attacks, patients should be advised to seek medical attention in an appropriate healthcare facility immediately in addition to treatment with Icatibant injection.

Icatibant side effects

The safety of icatibant was evaluated in three controlled trials that included 223 patients who received Icatibant injection 30 mg (n=113), placebo (n=75), or comparator (n=38). The mean age at study entry was 38 years (range 18 to 83 years), 64% were female, and 95% were white. The data described below represent adverse reactions observed from the two placebo-controlled trials, consisting of 77 patients who received Icatibant injection at a dose of 30 mg SC, and 75 who received placebo.

The most frequently reported adverse reactions (occurring in greater than 1% of patients and at a higher rate with Icatibant injection versus placebo) are shown in Table 1.

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. …

Drug interactions

Icatibant injection is a bradykinin B2 receptor antagonist and thereby has the potential to have a pharmacodynamic interaction with ACE inhibitors where Icatibant injection may attenuate the antihypertensive effect of ACE inhibitors. Clinical trials to date have excluded subjects taking ACE inhibitors.

About this medicine

Icatibant injection (icatibant) is a synthetic decapeptide with five non-proteinogenic amino acids. The chemical structure of icatibant acetate is presented in Figure 1.

Figure 1 Chemical Structure

Chemical name: D-Arginyl-L-arginyl-L-prolyl-L[(4R)-4-hydroxyprolyl]-glycyl-L[3-(2-thienyl)alanyl]-L­seryl-D-(1,2,3,4-tetrahydroisoquinolin-3-ylcarbonyl)-L[(3aS,7aS) octahydroindol-2-ylcarbonyl]-L­ arginine, acetate salt

Icatibant injection is provided as a sterile, isotonic, and buffered solution of icatibant acetate in a single-dose, prefilled syringe for subcutaneous administration. Each mL of the solution contains 10 mg of icatibant (free base) which is equivalent to 11.38 mg of icatibant acetate. Each prefilled syringe delivers 3 mL of solution equivalent to a 30 mg icatibant dose. The solution is clear and colorless.

The solution also contains sodium chloride (isotonicity reagent), glacial acetic acid (buffering agent), sodium hydroxide (pH adjuster) and water for injection with a pH of approximately 5.5. The solution does not contain preservatives. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 8c149392-d281-4311-880f-3be2b4752f40. Read the full official label on DailyMed.